| A comprehensive profile of recurrent glioblastoma B Campos, LR Olsen, T Urup, HS Poulsen Oncogene 35 (45), 5819-5825, 2016 | 242 | 2016 |
| VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance SR Michaelsen, M Staberg, H Pedersen, KE Jensen, W Majewski, ... Neuro-oncology 20 (11), 1462-1474, 2018 | 74 | 2018 |
| The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma SH Poulsen, T Urup, K Grunnet, IJ Christensen, VA Larsen, ML Jensen, ... European journal of nuclear medicine and molecular imaging 44, 373-381, 2017 | 73 | 2017 |
| The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients HS Poulsen, T Urup, SR Michaelsen, M Staberg, M Villingshøj, U Lassen Cancer management and research, 373-387, 2014 | 53 | 2014 |
| Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET) A Bashir, S Mathilde Jacobsen, O Mølby Henriksen, H Broholm, T Urup, ... Neuro-oncology 21 (12), 1595-1606, 2019 | 49 | 2019 |
| Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study T Urup, WZ Pawlak, PM Petersen, H Pappot, M Rørth, G Daugaard British journal of cancer 108 (10), 1994-1997, 2013 | 38 | 2013 |
| Cancer stem cells and the cellular hierarchy in haematological malignancies HE Johnsen, MK Kjeldsen, T Urup, K Fogd, L Pilgaard, M Boegsted, ... European journal of cancer 45, 194-201, 2009 | 38 | 2009 |
| Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients JN Jakobsen, T Urup, K Grunnet, A Toft, MD Johansen, SH Poulsen, ... Journal of neuro-oncology 137, 439-446, 2018 | 36 | 2018 |
| Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival SR Michaelsen, T Urup, LR Olsen, H Broholm, U Lassen, HS Poulsen Journal of Neuro-oncology 137, 533-542, 2018 | 32 | 2018 |
| Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients T Urup, SR Michaelsen, LR Olsen, A Toft, IJ Christensen, K Grunnet, ... Molecular Oncology 10 (8), 1160-1168, 2016 | 27 | 2016 |
| A prognostic model for glioblastoma patients treated with standard therapy based on a prospective cohort of consecutive non-selected patients from a single institution AA Abedi, K Grunnet, IJ Christensen, SR Michaelsen, A Muhic, S Møller, ... Frontiers in oncology 11, 597587, 2021 | 23 | 2021 |
| Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients T Urup, LM Staunstrup, SR Michaelsen, K Vitting-Seerup, M Bennedbæk, ... BMC cancer 17, 1-10, 2017 | 23 | 2017 |
| Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan T Urup, RH Dahlrot, K Grunnet, IJ Christensen, SR Michaelsen, A Toft, ... Acta Oncologica 55 (4), 418-422, 2016 | 17 | 2016 |
| Predicting survival of glioblastoma from automatic whole-brain and tumor segmentation of MR images S Pálsson, S Cerri, HS Poulsen, T Urup, I Law, K Van Leemput Scientific Reports 12 (1), 19744, 2022 | 15 | 2022 |
| DNA Methylation Levels of the ELMO Gene Promoter CpG Islands in Human Glioblastomas SR Michaelsen, D Aslan, T Urup, HS Poulsen, K Grønbæk, H Broholm, ... International Journal of Molecular Sciences 19 (3), 679, 2018 | 14 | 2018 |
| 18F-FET MicroPET and MicroMRI for Anti-VEGF and Anti-PlGF Response Assessment in an Orthotopic Murine Model of Human Glioblastoma MK Nedergaard, SR Michaelsen, T Urup, H Broholm, H El Ali, HS Poulsen, ... PLoS One 10 (2), e0115315, 2015 | 13 | 2015 |
| Outcome of bevacizumab therapy in patients with recurrent glioblastoma treated with angiotensin system inhibitors MD Johansen, T Urup, CB Holst, IJ Christensen, K Grunnet, U Lassen, ... Cancer Investigation 36 (9-10), 512-519, 2018 | 11 | 2018 |
| Implementing targeted therapies in the treatment of glioblastoma: previous shortcomings, future promises, and a multimodal strategy recommendation V Fougner, B Hasselbalch, U Lassen, J Weischenfeldt, HS Poulsen, ... Neuro-Oncology Advances 4 (1), vdac157, 2022 | 8 | 2022 |
| Biomarkers in recurrent grade III glioma patients treated with bevacizumab and irinotecan A Toft, T Urup, IJ Christensen, SR Michaelsen, B Lukram, K Grunnet, ... Cancer investigation 36 (2), 165-174, 2018 | 7 | 2018 |
| Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma T Urup, L Gillberg, K Kaastrup, MJS Lü, SR Michaelsen, VA Larsen, ... Molecular Oncology 14 (5), 964, 2020 | 6 | 2020 |
